Correct Answer: C. Streptococcus pyogenes
Streptococcus pyogenes (Group A Streptococcus, GAS) is a well-established producer of superantigens, the most clinically relevant being streptococcal pyrogenic exotoxins (SPEs) — particularly SPE-A, SPE-B, and SPE-C. Superantigens bypass normal antigen processing by directly cross-linking MHC class II molecules on antigen-presenting cells with T-cell receptors (TCRs), activating 5–20% of T cells (versus 0.01–0.1% in conventional immune responses). This massive, non-specific T-cell activation triggers excessive IL-2 and TNF-α release, causing the systemic inflammatory cascade seen in acute rheumatic fever (ARF), post-streptococcal glomerulonephritis (PSGN), and streptococcal toxic shock syndrome (STSS). In the Indian context, GAS remains the leading cause of ARF and rheumatic heart disease (RHD) — the most common acquired heart disease in children and young adults in India. SPE-B is a cysteine protease with superantigen properties, while SPE-A and SPE-C are classical superantigens. The presence of these toxins correlates with invasive disease severity and explains why certain M-protein serotypes (M1, M3, M12) are associated with severe invasive infections and post-infectious sequelae in Indian populations.
Why the other options are wrong
A. Clostridium perfringens — This is wrong because C. perfringens produces exotoxins (alpha, beta, epsilon, iota toxins) that are not superantigens. These are classical A-B toxins or pore-forming toxins causing gas gangrene and food poisoning through direct enzymatic damage (phospholipase C, collagenase), not through T-cell activation. NBE may pair this with toxin-producing organisms to trap students who confuse 'exotoxin' with 'superantigen.' B. Staphylococcus epidermidis — This is wrong because S. epidermidis is a coagulase-negative staphylococcus that primarily acts as a biofilm-forming commensal on skin. While S. aureus (not listed) produces superantigens (enterotoxins, TSST-1), S. epidermidis does not produce classical superantigens. It is a nosocomial pathogen causing device-related infections, not a superantigen producer. This is a distractor using a similar genus name. D. Vibrio cholera — This is wrong because V. cholerae produces cholera toxin (CTX), an A-B enterotoxin that activates adenylate cyclase via ADP-ribosylation of Gs proteins, causing massive secretory diarrhea. It is not a superantigen; it works through direct enzymatic modification of host signaling, not T-cell cross-linking. This is a classic toxin-producing organism trap designed to confuse toxin-producing bacteria with superantigen producers.
High-Yield Facts
- Streptococcal pyrogenic exotoxins (SPE-A, SPE-B, SPE-C) are the superantigens produced by GAS; SPE-B is a cysteine protease with superantigen activity.
- Superantigens activate 5–20% of T cells by directly cross-linking MHC class II and TCR, compared to 0.01–0.1% in conventional antigen presentation.
- GAS superantigens drive post-streptococcal sequelae: acute rheumatic fever (ARF), post-streptococcal glomerulonephritis (PSGN), and streptococcal toxic shock syndrome (STSS).
- M1 and M3 serotypes of GAS are associated with invasive disease and superantigen-mediated complications in Indian populations.
- Staphylococcus aureus (not S. epidermidis) produces superantigens: enterotoxins (SEA, SEB, SEC) and toxic shock syndrome toxin-1 (TSST-1).
Mnemonics
GAS Superantigens = SPE Streptococcus pyogenes → Pyrogenic Exotoxins (SPE-A, SPE-B, SPE-C). Remember: GAS = superantigen producer; Staph aureus = also superantigen (enterotoxins, TSST-1), but S. epidermidis ≠ superantigen. Superantigen Sequelae in India ARF-PSGN-STSS: Acute Rheumatic Fever, Post-Streptococcal GlomerulonePhritis, Streptococcal Toxic Shock Syndrome — all driven by GAS superantigens. ARF/RHD is the #1 acquired heart disease in Indian children.
NBE Trap
NBE pairs "toxin-producing organism" with "superantigen" to trap students who conflate exotoxins (C. perfringens, V. cholerae) with superantigens. The key discriminator is mechanism: superantigens activate T cells via MHC-TCR cross-linking; classical exotoxins work via direct enzymatic damage.
Clinical Pearl
In Indian clinical practice, a child presenting with acute rheumatic fever (carditis, polyarthritis, chorea) 2–3 weeks after a sore throat caused by GAS is experiencing superantigen-driven post-infectious sequelae. Recognizing GAS as the superantigen producer explains why anti-inflammatory therapy (aspirin, corticosteroids) and long-term penicillin prophylaxis are critical — the damage is immunological, not just infectious.
_Reference: Jawetz, Melnick & Adelberg's Medical Microbiology (Chapter on Streptococcus); Harrison's Principles of Internal Medicine (Chapter 297, Streptococcal Infections); Park's Textbook of Preventive and Social Medicine (Rheumatic Fever epidemiology in India)_